Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: U-500R; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 204
States / cities: Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more

Conditions: Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4,048 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Orange, California • Newark, Delaware • Chicago, Illinois + 9 more

Conditions: Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Steroid Cell Tumor
Interventions: Paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 85
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 66 more

Conditions: Type 1 Diabetes Mellitus
Interventions: etanercept; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Gestational Diabetes Mellitus
Interventions: STOPPING-GDM; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 20 Years · Female only
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Diabetes Mellitus, Type 1
Interventions: Teens.Connect; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Type II Diabetes
Interventions: Best-Worst Scaling (Case 2), Discrete Choice Experiment; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 1,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
Interventions: Adrenalectomy, Observation; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer
Interventions: Expressive Writing, Fact Writing (Control); Behavioral
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 18 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Breast Cancer
Interventions: Dato-DXd; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: Mobile health application; Other
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes, Gastric Bypass
Interventions: Mixed Meal Tolerance test, Hyperglycemic clamp; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 19 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 1 Diabetes
Interventions: Parental Support, Diabetes Education; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year to 6 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Richmond, Virginia

Conditions: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Chronic Kidney Diseases, Healthy Lifestyle
Interventions: Individualized basic need navigation and lifestyle coaching and skills training, Enhanced usual care; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Male Hypogonadism
Interventions: Testosterone; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 30
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 26 more

Conditions: Pancreatic Carcinoma
Interventions: Best Practice, Quadratus Lumborum Block, Quality-of-Life Assessment, Questionnaire Administration; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes
Interventions: Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Chula Vista, California • Orlando, Florida

Conditions: Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
Interventions: TT-00420, Nab-Paclitaxel; Drug · Combination Product
Lead sponsor: TransThera Sciences (Nanjing), Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Duarte, California • Chicago, Illinois • New Brunswick, New Jersey + 3 more

Conditions: Hypogonadism
Interventions: Testerone Transdermal System; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Miramar, Florida • Omaha, Nebraska • San Antonio, Texas

Conditions: Primary Ovarian Insufficiency, Unexplained Infertility
Interventions: Dehydroepiandrosterone, Placebo; Dietary Supplement · Other
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 37 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus
Interventions: MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200); Drug · Device
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 8 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Diabetes, Type 1
Interventions: Technosphere Insulin, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Questionnaires/Interviews; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 10 Years to 13 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: University Park, Pennsylvania

Search by objective public record fields.

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Continuation of the nuMoM2b Heart Health Study

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Islet After Kidney Transplant for Type 1 Diabetes

Supporting American Indian/Alaska Native Mothers and Daughters in Reducing Gestational Diabetes Risk

A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect

Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

Writing About Experiences With Ovarian Cancer

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population

Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery

Parental Management of Young Children's Diabetes

Basic Needs Navigation Intervention to Address Multidimensional Adversity in African Americans With Diabetic Kidney Disease

Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism

Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Tweens to Teens Project at Penn State